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In recent years, immunotherapy has produced encouraging results in a rapidly increasing number of solid tumors. The
responsiveness of bladder cancer to immunotherapy was first established in nonmuscle invasive disease in 1976 with intravesical
instillations of bacillus Calmette-Gue´rin (BCG). Very recently immune checkpoint inhibitors demonstrated good activity and
significant efficacy in metastatic disease. In particular the best results were obtained with programmed death-ligand-1 (PD-L1) and
programmed death-1 (PD-1) inhibitors, but many other immune checkpoint inhibitors, including anti-cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4) antibodies, are currently under investigation in several trials. Simultaneously other therapeutic
strategies which recruit an adaptive immune response against tumoral antigens or employ externallymanipulated tumor infiltrating
lymphocytes might change the natural history of bladder cancer in the near future. This review describes the rationale for the use
of immunotherapy in bladder cancer and discusses recent and ongoing clinical trials with checkpoint inhibitors and other novel
immunotherapy agents.
1. Introduction
As well documented by a large body of research, tumor cells
are able to avoid control and destruction by the immune
system using a range of complex and often overlappingmech-
anisms that lead to disruption of key components involved
in the effective antitumor response [1–4]. Immune system
should recognize and eliminate tumor cells that can avoid
this immune response by disrupting antigen presentation,
either through downregulation of major histocompatibility
complex (MHC) class I molecules or by disabling antigen-
processing machinery. Alternatively, or in addition, tumors
can be able to suppress the immune system by a disruption of
molecular pathways involved in controlling T-cell inhibition
and activation or by recruiting immunosuppressive cell types,
such as regulatory T-cells (Tregs) and myeloid-derived sup-
pressor cells. Another mechanism that tumor cells may use
in order to suppress immune activity is the release of factors,
including adenosine and prostaglandin E2 and the enzyme
indoleamine 2,3-dioxygenase (IDO) [3].
The robust progress in the understanding of these tumor
immune-evasion strategies has resulted in the evaluation of
various approaches to target and harness the patient’s
immune system directly to kill tumor cells. Consequently, in
recent years, new generation of immunotherapy has pro-
duced relevant results in a rapidly increasing number of
solid tumors. With the exception of the therapeutic vaccine
sipuleucel-T that was approved for the treatment of prostate
cancer in 2010, all these practice-changing results have
been obtained with immune checkpoint inhibitors. Two
major classes of drugs have been tested: anti-cytotoxic T-
lymphocyte-associated protein (CTLA)-4 antibodies and
anti-programmeddeath-1 (PD-1) or anti-programmeddeath-
ligand-1 (PD-L1) antibodies. Starting from melanoma, these
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drugs have produced positive results in many solid tumors.
Differently from classical chemotherapy and from the major-
ity ofmolecularly targeted agents that act by directly targeting
tumor cells, all the immune checkpoint inhibitors act by
targeting the patient’s immune system against tumor cells.
First important results have been obtained with ipili-
mumab in patients affected by malignant melanoma [5, 6].
Subsequently, also nivolumab and pembrolizumab demon-
strated efficacy in these patients [7–9].
Following the results obtained in patients with malignant
melanoma, immune checkpoint inhibitors have produced
clear evidence of efficacy, within randomized controlled
trials, in the treatment of patients with advanced non-small-
cell lung cancer (NSCLC). Namely, in patients who have
failed first-line platinum-based chemotherapy, nivolumab,
pembrolizumab, and atezolizumab, all given as single agents,
demonstrated an improvement in overall survival compared
to docetaxel [10–13]. In addition, pembrolizumab has also
shown superiority compared to platinum-based chemother-
apy, when given as first-line in a population of advanced
NSCLC patients, selected for the high expression of PD-L1
in tumor cells [14].
Nivolumab has also been approved for the second-line
treatment of advanced renal cell cancer, following the results
of a randomized phase III trial showing an improvement in
overall survival compared to everolimus [15].
Furthermore, the list of other solid tumorswhere immune
checkpoint inhibitors have already produced evidence of
activity and efficacy and where these drugs are currently
under investigation is long.
2. Rationale for Immunotherapy in
Urothelial Cancer
The efficacy of immunotherapy in bladder cancer was first
established in 1976 when Morales et al. proved for the
first time that intravesical instillations of bacillus Calmette-
Gue´rin (BCG) were efficient in preventing recurrences of
high-risk nonmuscle invasive urothelial bladder cancer and
in treating carcinoma in situ [16]. Although the mechanism
of action of BCG is not yet clear even after forty years from
the first evidence, it seems to stimulate a cytotoxic response
trough the combination of antigenic fragments, processed by
bladder cancer cells, with the histocompatibility complex on
the tumor cells surface [17].
After this initial success, many other attempts have been
made to take advantage of directing T-cells against bladder
cancer cells both in the localized and advanced disease,
using activating cytokines such as interleukin- (IL-) 2 and
interferon- (IFN-) alfa-2B [18, 19]. These drugs have shown
limited benefits in achieving disease control.
A turning point took place on the second decade of this
century when immune checkpoint inhibitors arrived on the
scene. Contrary to the previous strategy this new class of
monoclonal antibodies aims to reduce inhibitory signaling
instead of directly stimulating T-cells.
The first receptor to be targeted was CTLA-4, a molecule
expressed on activated CD4 and CD8 T-cells. CTLA-4 com-
petes with CD28 for the interaction with the costimulatory
CD80-CD86 molecules on antigen presenting cells (APCs).
While the latter interaction promotes T-cells activation and
effector functions, CTLA-4-CD80/86 inhibits T-cell activa-
tion in lymphoid tissues [20]. Two monoclonal antibodies
targeting CTLA-4 have been developed: ipilimumab and
tremelimumab, whose effect is to shift T-cell equilibrium
toward activation.
It has been further observed that tumor cells might
evade immune system surveillance through the interaction
between PD-L1 and PD-L2 with their receptor PD-1, which is
expressed onCD4 andCD8T-cells, Tregs, B-cells, andnatural
killer (NK) cells. Acting directly among tumor microenvi-
ronment, drugs directed against either PD-1 or PD-L1 are
usually characterized by lower adverse effects than CTLA-4
inhibitors [21].
Furthermore, many other immune checkpoint receptors
are currently under investigation in several trials, as potential
therapeutic targets. Simultaneously other therapeutic strate-
gies which recruit an adaptive immune response against
tumoral antigens might change the natural history of bladder
cancer in the near future [20].
Bladder cancer usually shows some biological features
that have been associated with better response to immun-
otherapies. First of all, an adaptive immune response against
cancer cells requires the presence tumor antigens endowed
with a good immunogenicity.More themutation board,more
likely this kind of antigens is expressed in tumor microen-
vironment. Bladder cancer is often characterized by a high
mutation load. Moreover PD-L1 expression on the surface of
tumor cells has been correlated with a higher-stage, sug-
gesting good response to PD1/PD-L1 antagonist, although
the results of different trials did not observe the association
between PD-L1 expression and tumor response rate [22].
Indeed, themajor challenge that is going to be faced in the
next years is to find predictive factors granted by greater
sensibility and specificity.
3. PD-L1 Inhibitors
3.1. Atezolizumab. Atezolizumab is an engineered human
monoclonal antibody against PD-L1, able to inhibit the inter-
action between PD-L1 and its receptor PD-1. A multicentre,
nonrandomized, phase II trial (IMVigor 210) evaluated the
efficacy and safety profile of intravenous atezolizumab (given
every three weeks at the dose of 1200mg) in two different
cohorts of locally advanced or metastatic urothelial carci-
noma: cohort A included treatment na¨ıve patients, ineligible
for cisplatin; cohort B included patients progressing during
or after platinum-based chemotherapy. PD-L1 expression on
tumor infiltrating immune cells was assessed prospectively
by immunohistochemistry. On the basis of PD-L1 expression,
patients were categorized in three subgroups: IC0 (<1%), IC1
(≥1% but <5%), and IC2/3 (≥5%).
In cohort B, among the 310 evaluable patients overall
response rate (ORR) was 15% (95% CI, 11–20) with 5% of
complete responses. High levels of PD-L1 expression were
associated with better ORR (27%; 95% CI, 19–37). After a
median follow-up of 11.7 months, the median duration of
response has not yet been reached, and durable responses
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have been recorded also in patients with poor prognostic
features [23] (Table 1). Median overall survival was 11.4
months in patients in the IC2/3 group, 8.8 months in the
IC1/2/3 group, and 7.9months in the whole cohort of patients.
Due to these positive results, Food andDrug Administra-
tion (FDA) approved in May 2016 atezolizumab for the treat-
ment of patients with locally advanced or metastatic urothe-
lial carcinoma progressing during or following platinum-
containing chemotherapy or within 12 months of either
adjuvant or neoadjuvant platinumchemotherapy.The recom-
mended dose is 1200mg, given as an intravenous infusion
every three weeks.
As for the cohort A of patients who were not eligible for
cisplatin (𝑛 = 123), the ORR was 23% (95% CI, 16–31) in all
patients, with slight but not statistically significant differences
among PD-L1 subgroups. ORR was 28% (95% CI; 14–47)
in patients with high PD-L1 expression and 21% (95% CI;
9–36) in patients PD-L1 negative. After a 17.2 months median
follow-up duration, median overall survival (OS) was 15.9
months (95% CI; 10.4 to not estimable) in all patients [24]
(Table 1).
In the attempt of identifying predictive factors of activity
and efficacy of atezolizumab, in addition to PD-L1 determi-
nation, authors evaluated also Cancer Genome Atlas gene
expression and mutation load. In both cohorts, responses
were more frequent in the Luminal II subtype and in patients
with higher mutation load, irrespective of PD-L1 expression.
Moreover, in cohort B, PD-L1 expression and responses to
atezolizumab were most closely associated with immune
activation gene expression (e.g., interferon-𝛾-inducible T-
helper-1-type chemokines: CXCL9 and CXCL10) and CD8 T-
cell infiltration [23, 24].
Treatment with atezolizumab was well tolerated in both
cohorts, with serious adverse events (AEs) occurring in 15-
16% of patients, and only a treatment-related death for sepsis
occurred in cohort A [23, 24].
A phase 3 trial is evaluating the efficacy of atezolizumab
compared to second-line chemotherapy in patients with
locally advanced ormetastatic urothelial carcinoma progress-
ing to platinum-based treatment; furthermore, several stud-
ies are ongoing investigating atezolizumab monotherapy or
in combination with chemotherapy or other immunological
agents in different stages of disease (Table 2).
3.2. Durvalumab. Durvalumab (MEDI4736) is a selective,
high-affinity, human monoclonal antibody directed against
PD-L1. A phase I/II multicentre dose escalation and dose-
expansion study is ongoing in patients with advanced solid
tumors, to evaluate safety, tolerability, and antitumor activ-
ity of durvalumab monotherapy. In June 2016, Massard
et al. published first results about patients with urothelial
carcinoma progressing on or ineligible for cisplatin-based
therapy (𝑛 = 61). Durvalumab, at the dose of 10mg/kg,
was administered intravenously every two weeks, for up to
twelve months. Patients were categorized on the basis of PD-
L1 expression, assessed either on tumor cells or on immune
cells (adopting a cutoff of 25%). Among the 42 patients
evaluable for response, the ORR was 31% (95% CI, 17.6–47.1).
A greater antitumor activity was observed in the PD-L1
positive subgroup (46.4%; 95% CI, 27.5–66.1); in the PD-L1
negative patients the ORR was 0% (95% CI, 0.0–23.2). At the
time of analysis, responses were ongoing in 12 of 13 patients
with a median duration of response not yet reached (range:
4.1 to 49.3 weeks). Treatment tolerance was optimal; serious
AEs occurred in 4.9% of patients, with no treatment-related
deaths [25] (Table 1).
An update of this study has been presented at 2017 ASCO
GenitourinaryCancer Symposium. Efficacy analysis included
103 patients with a median follow-up of 7.3 months. The
ORR was 20.4% (13.1–29.5) in the overall population and
29.5% (18.5–42.6) in the PD-L1 positive subgroup versus 7.7%
(1.6–20.9) in the PD-L1 negative patients [26].
In February 2016 the FDA granted a breakthrough ther-
apy designation to durvalumab as a treatment for PD-L1-
positive inoperable or metastatic urothelial bladder cancer
patients progressing on platinum-based treatment.
Several trials are ongoing in urothelial carcinoma patients
investigating activity of durvalumab, alone or in combination
with the anti-CTLA4 tremelimumab (Table 2).
3.3. Avelumab. Avelumab is a fully human anti-PD-L1 mon-
oclonal antibody. A large phase Ib trial is ongoing, inves-
tigating safety, tolerability, and clinical activity of avelumab
in patients with locally advanced or metastatic solid tumors,
including patients with urothelial carcinoma whose disease
progressed after platinum-based chemotherapy or who were
platinum ineligible. Avelumab showed preliminary safety and
efficacy in a cohort of 44 patients [27] (Table 1), so an
additional cohort of 129 eligible urothelial carcinoma patients
was enrolled and received avelumab, 10mg/kg, every two
weeks until confirmed progression, unacceptable toxicity, or
withdrawal. Preliminary data about 109 patients with at least
four months of follow-up were presented at 2016 ESMO
Congress: confirmed ORR was 16.5% (95% CI, 10.1–24.8),
with 3 complete and 15 partial responses. PFS rate at 12 weeks
was 35.6 (95% CI; 26.5–44.7). Treatment was well tolerated;
grade 3-4 treatment-related adverse events occurred in 9% of
patients; and pneumonitis resulted in one treatment-related
death [28]. An update of this study was reported at 2017
ASCO Genitourinary Cancer Symposium. Data were avail-
able in 153/241 patients with at least six months of follow-
up: ORR was 17.6% (95% CI, 12.0–24.6), 88.9% of responses
were ongoing at the time of analysis, and median OS was 7.0
months (95% CI, 5.6–11.1). Based on a ≥5% PD-L1 expression
cutoff assessed prospectively on tumor cells, ORR was sig-
nificantly higher in PD-L1 positive patients (25.0%; 95% CI,
14.4–38.4) compared with PD-L1 negative subgroup (14.7%;
95% CI, 7.6–24.7; 𝑝 = 0.178). Treatment was well tolerated,
with only 7.5% grade ≥ 3 treatment-related AEs [29].
A randomized, open-label phase 3 trial of avelumab+best
supportive care (BSC) versus BSC alone as maintenance ther-
apy after first-line platinum-based chemotherapy is ongoing
in patients with advanced urothelial cancer (Table 2).
4. PD-1 Inhibitors
4.1. Nivolumab. Nivolumab is a fully human anti-PD-1 mon-
oclonal antibody, currently approved for the treatment for
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Table 2: Ongoing clinical trials of anti PD-L1 and anti PD-1 immune checkpoint inhibitors in metastatic urothelial cancer.
Study Phase Regimen Primary endpoints
Planned
number of
pts or pts
enrolled
Status
Atezolizumab NCT02302807(IMVigor 211) III
Atz 1200mg IV d1 q3w versus
CT (Vnf 320mg/m2 or Txl
175mg/m2 , or Txt 75mg/m2 )
IV d1 q3w
OS 932 Active, not recruiting
NCT02807636
(IMVigor 130) III
Atz 1200mg IV d1 + CT (Crb
AUC 4.5 IV d1 + Gem
1000mg/m2 IV d1,8 q3w)
versus Placebo + CT
OS, PFS and Safety 435 Currently recruiting
NCT02989584 II
Atz 1200mg IV d8 q3w + Gem
1000mg/m2 IV d1,8 + Cis
70mg/m2 d1 q3w
(maintenance in phase II)
Safety 30 Currently recruiting
NCT02298153
(ECHO-110) I
Atz 1200mg IV q3w +
Epacadostat 25mg OS BID as
starting dose, followed by dose
escalations.
Safety 118 Currently recruiting
NCT02928406 III Atz 1200mg IV q3w Safety 1000 Active, not recruiting
NCT02655822 I
CPI-444 in 3 different
schedules versus CPI-444 +
Atz IV
Safety, ORR,
median AUC of
CPI-444
534 Currently recruiting
NCT02543645 I/II Varlilumab 0.3 or 1 or 3mg/kg+ Atz 1200mg IV q2w Safety, ORR 55 Currently recruiting
Durvalumab NCT02516241 III IV Drv +/− IV Trm versus CT(platinum + Gem) PFS, OS 1005 Active, not recruiting
NCT02546661
(Biscay) I
(A) Drv + AZD4547
(B) Drv + olaparib
(C) Drv + AZD1775
(D) Drv
(E) Drv + Vistusertib
Safety 110 Currently recruiting
NCT02527434 II IV Trm versus IV Trm + IVDrv versus IV Drv ORR 66 Currently recruiting
NCT02643303 I/II IV Drv + IV Trm +/− IT/IMPolyICLC
Recommended
combination dose,
safety, ORR, PFS
and OS
102 Active, not recruiting
NCT02318277 I/II
Drv IV q2w + OS
INCB024360 25mg BID
followed by dose escalations.
DLT, ORR 185 Currently recruiting
Avelumab
NCT02603432
(JAVELIN
Bladder 100)
III Avl IV q2w + BSC versus BSC OS 668 Currently recruiting
Nivolumab NCT02387996 II IV Niv ORR 242 Active, not recruiting
NCT02897765 I Niv IV 240mg q2w +/−NEO-PV-01 SC + Adj Safety 90 Currently recruiting
NCT02496208 I OS cabozantinib-s-malate +IV Niv +/− IV Ipi Safety and DLT 66 Currently recruiting
NCT01928394
(Checkmate
032)
I/II
IV Niv +/− IV Ipi (different
schedules) +/− OS
Cobimetinib
ORR 1150 Currently recruiting
NCT02636036
(SPICE) I IV Niv + IV Enadenotucirev MTD 30 Currently recruiting
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Table 2: Continued.
Study Phase Regimen Primary endpoints
Planned
number of
pts or pts
enrolled
Status
NCT02834013
(DART) II Niv IV d1,15,29 + Ipi IV d1 q6w ORR 334 Active, not recruiting
NCT02614456 I
Phase 1: IFN-𝛾 SC 50 𝜇g/m2
d1–7
Phase 2: IFN-𝛾 SC QD + Niv
IV d1 q2w
Phase 3: Niv IV d1 q3w
Safety, DLT 15 Currently recruiting
Pembrolizumab NCT02717156 II Pmb IV d1 + EphB4-HSA IVd1,8,15 q3w Safety 60 Active, not recruiting
NCT02925533 I IV B-701 + IV Pmb q3w Safety 12 Currently recruiting
NCT02560636
(PLUMMB) I IV Pmb + RT MTD, Safety 34 Currently recruiting
NCT02351739
(Keynote 143) II IV Pmb +/− ACP-196 ORR 75 Active, not recruiting
NCT02500121 II Pmb 200mg IV d1 q3w versusplacebo 6 months PFS 200 Currently recruiting
NCT02853305
(Keynote 361) III
Pmb 200mg IV d1 q3w +/−
CT versus CT (platinum +
Gem)
PFS, OS 990 Currently recruiting
NCT02619253 I/II Pmb 200mg IV d1 q3w +Vorinostat OS d1–14 q3w Safety 42 Currently recruiting
NCT02826564 I
Stereotactic body
radiotherapy prior to or
concurrent with IV Pmb
Safety, selection of
the sequence arm
with a DLT < 20%
20 Currently recruiting
NCT02880345
(Radvax) Pilot
IV Pmb + hypofractionated
RT (2 different regimens) Safety 14 Active, not recruiting
NCT02437370 I IV Pmb + IV Txt versus IVPmb versus IV Gem MTD 38 Currently recruiting
NCT02043665
(Keynote 200) I
(A) CVA21
(B) CVA21 + Pmb ORR 60 Currently recruiting
NCT02581982 II Pmb 200mg IV d1 + Txl IVd1,8 q3w ORR 27 Currently recruiting
NCT01174121 II
Cyclophosphamide and
fludarabine + Pmb + young
TIL
Rate of tumor
regression 290 Currently recruiting
NCT03006887 I Pmb 200mg IV d1 +Lenvatinib OS 20mg QD q3w Safety, DLT 10 Active, not recruiting
NCT02501096 I/II Pmb 200mg IV d1 +Lenvatinib OS QD q3w MTD, ORR, DLT 250 Currently recruiting
NCT02346955
(MK-6018-001) I
Multidose escalation of
CM-24 +/− Pmb 200mg IV Safety, DLT 196 Currently recruiting
NCT02452424 I/II Dose escalation of OSPLX3397 + Pmb 200mg IV Safety 400 Currently recruiting
NCT02432963 I IV Pmb + SC MVA-p53Vaccine Tolerability 19 Currently recruiting
NCT02393248 I/II
Phase 1: dose
escalation/expansion of
INCB054828
Phase 2: INCB054828 +
Pmb/CT (Txt or Cis + Gem)
MTD,
pharmacodynamics 150 Currently recruiting
NCT02443324 I IV Pmb + Ramucirumab IVd1 q3w DLT 155 Currently recruiting
NCT02856425 I IV Pmb + OS Nintedanib MTD 18 Currently recruiting
Atz: atezolizumab; Avl: avelumab; Cis: cisplatin; Drv: durvalumab; Gem: gemcitabine Ipi: ipilimumab; Trm: tremelimumab; Txl: taxol; Txt: taxotere; Niv:
nivolumab; Pmb: pembrolizumab.
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Table 3: Ongoing clinical trials of anti-CTLA-4 immune checkpoint inhibitors in metastatic urothelial cancer.
Study Phase Regimen Primaryendpoints
Planned
number of
pts or pts
enrolled
Status
Ipilimumab
NCT01524991 II
IV gemcitabine 1000mg/m2 d
1,8 + cisplatin 70mg/m2 d1 q3w.
IV Ipi 10mg/kg d1 (start c3)
1 year OS 36 Active, not recruiting
NCT02496208 I OS cabozantinib-s-malate + IVNiv +/− Ipi Safety and DLT 66 Currently recruiting
NCT01928394 I/II IV Niv +/− Ipi (differentschedules) +/− cobimetinib ORR 1150 Currently recruiting
NCT02381314 I IV Ipi d1 q3w + IVenoblituzumab weekly Safety 84 Currently recruiting
NCT02834013 (DART) II IV Niv d 1,15,29 + IV ipilimumabd1 q6w ORR 334 Active, not recruiting
Tremelimumab
NCT02516241 III IV Drv +/− IV Trm versus CT(platinum + gemcitabine) PFS, OS 1005 Active, not recruiting
NCT02527434 II IV Trm versus IV Trm + IV Drvversus IV Drv ORR 66 Currently recruiting
NCT02643303 I/II IV Drv + IV tremelimumab +/−IT/IM PolyICLC
Recommended
combination
dose, safety, ORR,
PFS, and OS
102 Active, not recruiting
different malignancies, as front-line (melanoma) or second-
line monotherapy (NSCLC, renal cell cancer) or in com-
bination with ipilimumab (melanoma). An ongoing open-
label, two-stage, multiarm, phase I/II trial, Checkmate 032,
is evaluating safety and activity of nivolumab alone or in
combination with ipilimumab in subjects with advanced
or metastatic solid tumors. First results about a cohort of
patients with advanced urothelial carcinoma, who progressed
during or after platinum-based chemotherapy, treated with
nivolumab alone (3mg/kg intravenously every two weeks),
were published in October 2016. Eligible patients were
enrolled regardless of tumor cells PD-L1 expression that was
assessed retrospectively in pretreatment tumor biopsy speci-
mens collected within three months before treatment start. A
confirmedORRwas achieved in 24.4% (95%CI, 15.3–35.4) of
78 patients treated with nivolumab monotherapy, regardless
of PD-L1 tumor expression. There was no difference in the
ORR between patients with PD-L1 expression lower than 1%
(26.2%) and patients with PD-L1 expression ≥ 1% (24.0%).
However median OS was over 16.2 months in PD-L1 positive
tumors and 9.9 months in PD-L1 negative ones [30] (Table 1).
These data were recently confirmed by positive results
of phase II study, Checkmate 275, evaluating activity and
safety of nivolumab in 270 patients with metastatic blad-
der cancer progressing during or after first-line platinum-
based chemotherapy. Confirmed ORR was 19.6% (95% CI,
15.0–24.9) for all patients, 28.4% for patients with PD-L1
expression of 5% or greater, 23.8% for patients with PD-L1
expression of 1% or greater, and 16.1% for patients with PD-L1
expression of less than 1%.After amedian follow-up equal to 7
months, 24.4% of patients were still on treatment. Median
OS was 8.74 months in the whole study population; in the
subgroup of patients expressing PD-L1 ≥ 1% on tumor cells
median OS was 11.3 months, while in PD-L1 negative patients
it was 5.95 months. Cancer Genome Atlas gene expression
was also analysed on pretreatment tumor tissue: responses
were more frequent in the Basal I subtype according to Atlas
classification, which showed the strongest association with
interferon-y signature and the highest CD8 expression [31]
(Table 1).
At 2017 ASCO Genitourinary Cancer Symposium, pre-
liminary data about combination of nivolumab and ipili-
mumab have been presented. Ten patients with advanced
or metastatic urothelial cancer, refractory to nivolumab
monotherapy, were treated. Despite a slight increase of
immune-related toxicities, treatment was well tolerated and
showed a promising activity, with a disease control rate of
40% (one partial response and three stable disease were
reported) [32]. Of course, the number of patients described
in this preliminary experience is still too small to comment
the activity of the combination. Trials ongoing evaluating
nivolumab in combination with ipilimumab are shown in
Table 3 and will clarify the real potential of the immune-
therapy combination.
4.2. Pembrolizumab. Pembrolizumab is a humanized mon-
oclonal antibody directed against PD-1, which has shown
promising results for treatment of metastatic bladder can-
cer. Results about urothelial cancer patients’ cohort of the
nonrandomized, multicohort, open-label, phase 1b Keynote
012 basket trial were published in January 2017. Thirty-
three patients with advanced or metastatic urothelial cancer
with at least 1% PD-L1 expression in tumor cells or stroma
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were enrolled and treated with 10mg/kg intravenous pem-
brolizumab every two weeks, until progressive disease or
unacceptable toxicity. Treatment was generally well tolerated,
and only 9% of patients experienced serious adverse events.
Seven of 27 evaluable patients (26.0%; 95% CI, 11.0–46.0)
achieved partial or completed responses [33] (Table 1).
At 2017 ASCO Genitourinary Cancer Symposium, pre-
liminary data of phase II Keynote 052 trial have been
presented. In detail, this trial evaluated activity and safety of
pembrolizumab in cisplatin-ineligible patients with meta-
static or locally advanced bladder cancer, enrolled regard-
less of PD-L1 expression. However, PD-L1 expression was
prospectively assessed in tumor and immune cells, to bet-
ter characterize responding and nonresponding patients.
Patients received pembrolizumab 200mg intravenously every
three weeks, for up to 24 months of treatment. Among
patients with at least four months of follow-up, ORRwas 27%
(95% CI, 22–32); no data about activity according to PD-L1
expression were reported. The only data available have been
presented at ESMO 2016 Congress: ORR was 36.7% (95% CI,
19.9–56.1) in patients with 10% or greater PD-L1 expression
[34, 35] (Table 1).
Of note, a randomized phase III trial, Keynote 045 study,
compared pembrolizumab to chemotherapy (consisting of
either paclitaxel, docetaxel, or vinflunine according to Inves-
tigator’s choice) in 542 patients with locally advanced unre-
sectable or metastatic urothelial carcinoma recurring or pro-
gressing following platinum-based chemotherapy. A survival
benefit was shown in the pembrolizumab group (median OS
was 10.3 versus 7.4 months, hazard ratio for death, 0.73; 95%
CI, 0.59 to 0.91; 𝑝 = 0.002), regardless of PD-L1 expression;
also ORR was significantly improved in the pembrolizumab
group (21.1% versus 11.4%; 𝑝 = 0.001). These benefits
were similar across almost all subgroups examined, regard-
less of the type of chemotherapy or the presence of poor
prognostic factors, such as hepatic metastases. Fewer adverse
events for any grade occurred in the pembrolizumab group
compared to patients treated with chemotherapy (Table 1)
[36].
Various studies are ongoing investigating pembrolizumab
activity in combination with other systemic therapies and
radiotherapy (Table 2).
5. Drugs That Target CTLA-4
5.1. Ipilimumab and Tremelimumab. Safety and immunologic
pharmacodynamic effects of ipilimumab, an anti-CTLA-4
monoclonal antibody, have already been evaluated in the
neoadjuvant setting in a small phase II clinical trial. Twelve
patients with localized, high grade, urothelial carcinoma of
the bladder were treated with ipilimumab, at the dose of 3 or
10mg/kg. Safety profile of treatment was good. In all patients,
an increase in CD4 + T-cell population in both tumor tissue
and peripheral blood was found, probably positively related
to clinical benefit. Of note, eight patients showed tumor
regression: on radical cystectomy specimens, obtained after
neoadjuvant treatment, lower stages of disease were found
[37].
Several trials are now ongoing, to evaluate anti CTLA-4
antibody ipilimumab or tremelimumab, alone or in combi-
nation with nivolumab or durvalumab or chemotherapy or
other target therapies (Table 3). Results are not yet available.
6. Other Immunotherapies
Immunotherapy includes treatments that work in different
ways, not only limited to anti-PD-1, anti-PD-L1, or anti-CTL
A4 antibodies. There are many potential targets under study:
antigens on tumor cells surface, new immune-checkpoints,
and tumor microenvironment. Against some of these targets,
vaccines and monoclonal antibody are on development, even
if few results from clinical trials are available at the time.
6.1. Immune System Targets
6.1.1. Recombinant Interleukin-2. One of the first attempts of
immunotherapy foresaw the use of recombinant interleukin-
2 (rIL-2), a cytokine whose main function is to promote T-
cell differentiation and activation. In 1991, nine patients with
metastatic transitional bladder cancer were treated with a
continuous infusion of rIL-2 associated with lymphocytes
previously stimulated in vitro with the same cytokine. Unfor-
tunately none of the patients benefited from that treatment:
at the first radiological evaluation eight patients showed
progression disease and one patient had stable disease [18].
6.1.2. ALT-801. More recently at ASCO 2015 annual meeting,
preliminary results of a phase Ib/II study of cisplatin and
gemcitabine in combination with ALT-801, an IL-2/T-cell
receptor fusion protein, in advanced or metastatic urothelial
carcinoma were presented. Dose escalation expansion cohort
phase Ib study included both chemonaı¨ve and chemorefrac-
tory patients (group 1), whereas phase II expansion study
included only chemorefractory patients (group 2). 34 of the
62 enrolled patients were chemorefractory. Among these
patients, ORR was 35% (95% CI: 20–54%), and median OS
was 12.3months for group 1 (data not available for group 2 and
for chemona¨ıve patients). Almost all patients experienced
severe hematological toxicities [38].
6.1.3. B7-H3. B7H3, also known as CD276, is a ligand of
the B7 family, which also includes the better known PD-1
and PD-L1. Even if its receptor remains unidentified, B7H3
acts as coinhibitor of peripheral immune response, and its
expression seems to be particularly intense in urothelial
carcinoma and could correlate with poor prognosis [39]. A
dose escalation phase I trial is ongoing (NCT01391143) to
evaluate toxicity and potential antitumor activity of the mon-
oclonal antibody MGA271 (enoblituzumab), in patients with
various refractory cancers, including urothelial cancer that
express B7H3 antigen. Preliminary data were presented at
the 2015 Society for Immunotherapy of Cancer (SITC)
Annual Meeting. Treatment showed an optimal tolerability
with few severe adverse events and a promising activity in
patients with melanoma, prostate, and bladder cancer [40].
Another phase I trial (NCT02628535) is currently recruit-
ing participants to assess safety and establish the maximum
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tolerated dose (MTD) of MGD009, a humanized, Dual-
Affinity Retargeting, or DART molecule that recognizes
both B7-H3 and CD3. Patients must have B7-H3 positive
unresectable locally advanced or metastatic tumors, includ-
ing bladder cancer.
6.1.4. OX-40 and 4-1bb. OX-40 and 4-1bb, also known
respectively as CD134 and CD137, are both members of the
Tumor Necrosis Factor receptor (TNF-r) super-family. The
former is expressed onCD4 andCD8T-cell surfaces, the later
on NK and activated T-cells. The activation of both sig-
nal pathways promotes T-cell proliferation and survival.
Moreover OX-40 provides a stimulatory signal to effectors
and memory T-cell population, and an inhibitory signal to
regulatory T-cells [41, 42].
A phase I dose escalation study (NCT02315066) is cur-
rently recruiting participants to assess safety and potential
activity of an experimental OX-40 agonist alone or in combi-
nation with a 4-1bb agonist, in patients with various tumors,
including urothelial bladder carcinoma.
6.1.5. TILs. Another promising therapeutic strategy is the
infusion of externally manipulated T-cells that could be
extracted from tumor tissue, the so-called tumor infiltrating
lymphocytes or TILs, to give rapid immunity. TILs could be
simple expanded ex vivo or selected according to recognized
antigens. In a small open trial twelve patients underwent
surgery for stage IV bladder cancer and TILs from lymph
nodes draining metastatic tumors were collected. In six of
them, lymphocytes were infused after in vitro expansion
without any severe AEs. No data are available on the efficacy
of the treatment [43]. A phase II trial (NCT01174121) is now
recruiting patients with metastatic solid tumors, including
urothelial bladder cancer, with at least one resectable lesion
for TILs generation. Lymphocytes will be reinfused after con-
ditioning chemotherapy and pembrolizumab administration.
Results of another trial (NCT02863913), not yet open for
participants’ recruitment, will add important evidence. It is a
phase I dose escalation clinical trial to assess the safety of PD-
1 knockout engineeredT-cells in treatingmetastatic advanced
bladder cancer.
6.2. Tumor Targets
6.2.1. HER2. Human epidermal growth factor receptor 2
(HER2), also known as CD340, is a member of a big recep-
tor family, encoded by a protooncogene whose alterations
(almost amplification and overexpression) are common not
only in breast and gastric, but also in urothelial cancer.
HER2 target therapy had shown interesting activity in pre-
clinical studies and phase I clinical trials. Unfortunately no
difference in efficacy on addiction of trastuzumab to standard
chemotherapy with platinum and gemcitabine was detected
in advanced or metastatic urothelial carcinoma overexpress-
ing HER2 in a phase II clinical trial [44]. At 2017 ASCO
Genitourinary Cancer Symposium preliminary results of the
ongoing phase IIA MyPathway trial were presented. Twelve
patients with platinum-resistant HER2-positive metastatic
urothelial cancer have been enrolled, and at a median follow-
up of 5.4 months there were a CR, two PR, and two stabi-
lisation of disease [45]. Other clinical trials are still on-
going in these patients, testing other HER2 inhibitors,
like trastuzumab emtansine (NCT02999672) and Lapatinib
(NCT00949455, NCT02342587).
Alternative strategies are under development, looking
at HER-2 as a target for immunotherapy. A dendritic cell
vaccine called AdHER2, created using an individual’s own
immune cells, has been developed to stimulate the immune
system to recognizeHER-2. A phase I study (NCT01730118) is
now recruiting patients with various solid tumors and HER2
overexpression [46].
6.2.2. hCG-𝛽. Human Chorionic Gonadotropin beta-chain
(hCG-𝛽) is an antigen frequently expressed by epithelial
malignancies, including urothelial cancer. Elevated hCG-𝛽
serum levels and/or tissue expression are associated with
a more aggressive disease course. CDX-1307 is a human
monoclonal antibody against the APC mannose receptor
fused to hCG-𝛽 that acts like a vaccine. Internalized by APCs,
CDX-1307 is processed and hCG-𝛽 is presented as an antigen,
inducing specific cellular and humoral immune response.
A phase I trial demonstrated that CDX-1307 is well
tolerated and active, inducing consistent humoral and T-cell
responses when coadministrated with Granulocyte-Macro-
phage Colony-Stimulating Factor (GM-CSF) and Tall Like
Receptor (TLR) agonists, in patients with advanced epithelial
malignancies, including bladder cancer [47]. A phase II trial
(NCT01094496) to evaluate antitumor activity before and
after bladder surgery has recently been completed, but results
are not available.
6.2.3. MAGE-A. Melanoma associated antigen A (MAGE-A)
are a family of tumor specific antigens expressed in several
cancer cell types, but not in normal tissue, except for the
testis. MAGE-A proteins are recognized by cytotoxic T-cells
and are promising targets for immunotherapy [48]. Partial or
complete responses after MAGE-A target immunotherapy
have been reported, also for advanced bladder cancer. Par-
ticularly three of four heavily pretreated patients with high
expression of MAGE-A were enrolled in a small pilot clinical
trial. They were treated with subcutaneous injections of
autologous dendritic cells pulsed with MAGE-A3 epitopes
peptides, showing significant reduction of tumor burden
[49].
In a phase I/early II trial, patients with stage III or IV
malignancies, including three with bladder cancer, all
MAGE-3 positive, were randomized to three different escala-
tion dose levels of a recombinantMAGE-3 vaccine, associated
with fixed doses of an immunological adjuvant, in order to
further improve its immunogenicity. One of the bladder can-
cer patients showed a short-term almost complete response
of two months [50].
A dose escalation phase I trial (NCT02989064) is now
recruiting patients withMAGE-410 positive advancedmalig-
nancies, including bladder cancer. Treatment protocol pro-
vides the administration of autologous genetically modified
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MAGE A10 T-cells, and the primary endpoint is the evalua-
tion of safety and tolerability of that treatment.
6.2.4. NY-ESO-1. NY-ESO-1 is one of the most immuno-
genic tumor antigens, expressed in cancer and testis, but
not in other normal tissues (similarly to MAGE-A1). It
is expressed in approximately 25–30% of bladder cancers,
highly in advanced stages, and it is considered one of the best
targets for T-cell receptor (TCR) based immunotherapy in
solid cancers. NY-ESO-1-specific T-cell responses, induced in
cancer patients using NY-ESO-1 peptides, proteins, and
viruses encoding NY-ESO-1, are too weak to eradicate tumor
cells [51]. So to improve clinical response TCR gene therapy is
being developed. Two phase I trials (NCT02457650 and
NCT02869217) are currently recruiting participants withNY-
ESO-1-expressing malignancies to evaluate the safety and
feasibility of the administration of anti-NY-ESO-1 TCR engi-
neered autologous T-cells.
6.3. Peptide Personalized Vaccination. In the context of an
increasingly personalized medicine, an open-label, random-
ized phase II trial evaluated safety and efficacy of peptide
personalized vaccination compared to best supportive care in
eighty patients with advanced urothelial bladder cancer pro-
gressing after platinum-containing chemotherapy. Vaccina-
tion consisted in subcutaneous injections of maximum four
peptides chosen from a pool of thirty-one peptides according
to patients HLA type and specific peptide-reactive IgG titers.
PRwas observed in 9 (23%) patients in the experimental arm,
withmoCR. A significant improvement in OSwas also noted
(HR, 0.58; 95% CI, 0.34–0.99, 𝑝 = 0.049), but not in PFS.
Treatment was fairly well tolerated; almost all AEs were of
grade 1 or 2; there were no grade 4 AEs or treatment-related
deaths. Obviously, as the authors concluded, further large-
scale, randomized trials are needed to confirm these results
[52].
7. Discussion
The encouraging results recently obtained with several
immune checkpoint inhibitors [23–25, 27, 31, 36] raise enthu-
siasm about the future role of this therapeutic approach
for patients affected by advanced urothelial cancer. As well
known, standard treatment for these patients is platinum-
based chemotherapy, characterized by a difficult balance
between efficacy and treatment toxicity. The availability of
immune checkpoint inhibitors, both in patients who are
considered medically unfit for cisplatin and in patients who
have experienced disease progression after chemotherapy,
represents a clinically valuable opportunity. Interestingly, a
nonnegligible proportion of patients experience a durable
disease control, with a chance of long-survival that has been
observed, with the use of these drugs, in many types of solid
tumors.
However, similar to what is occurring also in other
tumors, knowledge about predictive factors of efficacy and
patients’ selection criteria for immunotherapy is still not
ideal and, within all the clinical trials, a relevant number
of patients failed to respond to the PD-1/PD-L1 checkpoint
blockades. From this point of view, it would be crucial to
identify a biomarker to predict the response to checkpoint
blockades. In principle, a perfect positive predictive value
could allow avoiding treating patients who are not going to
obtain any benefit, while a perfect negative predictive value
could allow not denying treatment to any of the patients
who could potentially benefit. Unfortunately, at the moment,
we have no biomarker with a good positive and negative
predictive value. The expression of PD-L1 has been studied
as a putative biomarker in many of the trials testing anti-
PD-1 and anti-PD-L1 drugs, but PD-L1 staining cannot be
used to accurately select patients for PD-1/PD-L1 pathway
blockade due to the low prediction accuracy and dynamic
changes [53]. Interestingly, tumor infiltrating immune cells
and molecules in the tumor microenvironment, alone or
along with PD-L1 expression, could be useful as predictive
factors [53]. Furthermore, gene analysis (gene signatures,
mutational landscape, and/or mismatch-repair deficiency)
could be useful if interesting preliminary evidence will be
confirmed and validated in further studies [23, 24].
The diffusion of immune checkpoint inhibitors in clinical
practice will imply the confidence of medical oncologists
with the diagnosis and management of typical side effects
associated with this therapeutic approach [54].
As for the applicability of trials results in clinical practice,
reasonably, we will have no direct comparisons between
different anti-PD-1 and anti-PD-L1 that are currently under-
going the clinical development. In the absence of obvious
differences in efficacy emerged in indirect comparison of
clinical trials, we do not know which is the best treatment
choice. Other issues that are not completely answered by the
evidence produced in clinical trials are the dose-response
relationship (recent evidence in melanoma with ipilimumab
suggests that higher dose is associated with higher efficacy
[55]) and the optimal duration of treatment (continuous until
disease progression or with planned “stop-and-go”).
Currently ongoing trials will clarify the role of immune
checkpoint agents as first-line treatment, compared to plat-
inum-based chemotherapy. Based on the results of these
trials, along with the trials testing other categories of immune
treatments, treatment paradigm for patients affected by
advanced urothelial cancer could be soon radically changed
compared to current guidelines.
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